Icon Plc (NASDAQ:ICLR) – Equities research analysts at KeyCorp raised their Q4 2017 earnings per share estimates for shares of Icon Plc in a research note issued on Sunday. KeyCorp analyst D. Hooker now forecasts that the medical research company will post earnings per share of $1.41 for the quarter, up from their prior forecast of $1.40. KeyCorp currently has a “Overweight” rating and a $125.00 target price on the stock. KeyCorp also issued estimates for Icon Plc’s Q1 2018 earnings at $1.42 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.52 EPS, Q4 2018 earnings at $1.56 EPS, FY2018 earnings at $5.97 EPS and FY2019 earnings at $5.89 EPS.
Other equities analysts have also issued reports about the company. SunTrust Banks, Inc. upgraded Icon Plc from a “hold” rating to a “buy” rating and raised their price target for the stock from $93.00 to $126.00 in a research report on Monday, July 31st. Jefferies Group LLC restated a “buy” rating on shares of Icon Plc in a research report on Sunday, July 30th. Credit Suisse Group restated a “buy” rating on shares of Icon Plc in a research report on Friday, July 28th. Zacks Investment Research upgraded Icon Plc from a “hold” rating to a “buy” rating and set a $120.00 price target on the stock in a research report on Thursday, August 24th. Finally, ValuEngine upgraded Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $121.00.
COPYRIGHT VIOLATION NOTICE: This article was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/15/q4-2017-earnings-forecast-for-icon-plc-iclr-issued-by-keycorp.html.
Icon Plc (ICLR) opened at $112.35 on Tuesday. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon Plc has a 1 year low of $73.76 and a 1 year high of $124.48. The company has a market capitalization of $6,132.17, a PE ratio of 21.74, a PEG ratio of 1.75 and a beta of 0.56.
Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.32 by $0.03. The firm had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.19 EPS.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IHT Wealth Management LLC lifted its holdings in Icon Plc by 16.9% in the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock worth $223,000 after buying an additional 24 shares during the period. IFP Advisors Inc lifted its holdings in Icon Plc by 3.0% in the 2nd quarter. IFP Advisors Inc now owns 2,299 shares of the medical research company’s stock worth $225,000 after buying an additional 67 shares during the period. Huntington National Bank lifted its holdings in Icon Plc by 5.0% in the 2nd quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after buying an additional 77 shares during the period. Bangor Savings Bank lifted its holdings in Icon Plc by 1.4% in the 2nd quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock worth $1,128,000 after buying an additional 161 shares during the period. Finally, Acrospire Investment Management LLC lifted its holdings in Icon Plc by 20.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 91.59% of the company’s stock.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.